<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix’ Proteomic Analysis of Innovative Immunotherapy Clinical Trial in Pancreas Cancer presented at European Society of Medical Oncology’s (ESMO) World Congress on Gastrointestinal Cancer

    The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.

    Biodesix Closes Series D Financing - August 2012

    Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.

    Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

    Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.

    Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

    Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

    Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

    Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.

    VeriStrat® Test Predicts Differential Treatment Benefit between Chemotherapy and Targeted Therapy for Lung Cancer Patients

    Analysis showed that the VeriStrat test was able to identify patients more likely to have a slower progression of disease with select treatments.

    Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

    Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.

    Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

    Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.

    Biodesix Secures Medicare Coverage for VeriStrat Test

    Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.

    Biodesix Appoints Vice President of Clinical Development & Medical Affairs

    Biodesix announced the appointment of Dominic Spinella, Ph.D., as Vice President of Clinical Development & Medical Affairs.